STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

Transmembrane proteins (TPs), also referred to as ‘integral membrane proteins’, make up between 70 % and 80 % of the total ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle vaccines that mimic viruses ...

A research team with Professor Neha Kamat used synthetic liposomes and bacterial extracts to generate immune responses ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Research on γ-secretase reveals its unique substrate recognition mechanism, offering potential for developing precise ...

Aggression is a complex behavior dependent on numerous factors such as personal experiences, upbringing, social context, personality and genetics. Florian Reichmann and his team at the Med Uni Graz ...

Certain genes may increase your risk of developing MASH. Family history may play a role in your likelihood of developing the ...

Using artificial intelligence, researchers show how γ-secretase recognizes substrates – an important advance for fundamental ...